Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer

European Journal of Nuclear Medicine

Volumn 25, Issue 9, 1998, Pages 1244-1247

  Bury, T ^a   Barreto, A ^a   Daenen, F ^a   Barthelemy, N ^a   Ghaye, B ^a   Rigo, P ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bone metastasis; Lung neoplasm; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE METASTASIS; BONE SCINTISCANNING; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS;

AGED; BONE AND BONES; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, EMISSION-COMPUTED;

BIOLOGICAL ORGANS; BONE; DIAGNOSIS; DISEASES; ELECTRONS; FLUORINE; NUCLEAR MEDICINE; PATHOLOGY; POSITRONS; SURGERY;

BONE METASTASIS; BONE SCINTIGRAPHY; FLUORINE-18; HIGH SENSITIVITY; LUNG CANCER; LUNG NEOPLASM; METASTATIC DISEASE; MORPHOLOGICAL IMAGING; NON SMALL CELL LUNG CANCER; RADIOGRAPHIC TECHNIQUE;

POSITRON EMISSION TOMOGRAPHY;

EID: 0031664230     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050291     Document Type: Article

References (25)

1. Standord W, Spivey C, Larsen G et al. Results of treatment of primary carcinoma of the lung: analysis of 3000 cases. J Thorac Cardiovasc Surg 1976; 72: 441.
2. Nolop K, Rhodes C, Brudin L, Beanay R, Krausz T, Jones T, Hughes J. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60: 2682-2689.
3. Rege S, Hoh C, Glaspy J, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82-90.
4. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
5. Patz EF, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-(F18)-2-deoxy-\delta-glucose. Radiology 1994; 191: 379-382.
6. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371-377.
7. Bury T, Corhay JL, Paulus P, et al. La tomographic à émission de positons dans l'évaluation de l'extension ganglionnaire intrathoracique du cancer bronchique non à petites cellules: étude préliminaire chez 30 patients. Rev Mal Respir 1996; 9: 410-114.
8. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of PET imaging in non-small cell lung cancer. Eur Respir J 1996; 9: 2560-2564.
9. Chin R, Ward R, Keyes J, et al. Mediastinal staging of non-small cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995; 152: 2090-2096.
10. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-1266.
11. Valk P, Pounds T, Hopkins D, et al. Staging of non-small cell lung cancer by whole-body positron emission imaging. Ann Thorac Surg 1995; 60: 1573-1582.
12. 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997; 10: 2529-2534.
13. Krasnow A, Hellman R, Timins M, Collier D, Anderson T, Isitman A. Diagnostic bone scanning in oncology. Semin Nucl Med 1991; 21: 107-141.
14. Tisi G, Friedman P, Peters R, Pearson G, Carr D, Lee R, Selawry O. Clinical staging of primary lung cancer. Am Rev Respir Dis 1983; 127: 659-664.
15. Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest 1990; 97: 1052-1058.
16. Napoli LD, Hansen HH, Muggia FM, Twigg HL. The incidence of osseous involvement in lung cancer, with special reference to the development of osteoblastic changes. Radiology 1973; 108: 17-21.
17. Oyamada H, Tabei Y, Yoneyama T, Eguchi K Orii H, Terni S. Whole-body scintigram and stage classification of patients with adenocarcinoma of the lung. Tohoku J Exp Med 1978; 124: 145-151.
18. Cowan RJ, Young KA. Evaluation of serum alkaline phosphatase determinations in patients with positive bone scans. Cancer 1973; 32: 887-889.
19. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. In: Warburg O, ed. Metabolism of tumors. London: Constable; 1930:254-270.
20. Som P, Atkins HL, Bandoypadhyay D et al. A fluorinated glucose analog, 2-fluoro-2-Deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-675.
21. Merrick MV, Merrick JM. Bone scintigraphy in lung cancer: a reappraisal. Br J Radiol 1986; 59: 1185-1194.
22. Torynos K, Garcia O, Karr B, Le Beaud R. A correlation study of bone scanning with clinical and laboratory findings in the staging of non-small cell lung cancer. Clin Nucl Med 1991; 16: 107-109.
23. Michel F, Soler M, Imhof E, Perruchoud AP. Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax 1991; 46: 469-473.
24. Donato A, Ammerman G, Sullesta O. Bone scanning in the evaluation of patients with lung cancer. Ann Thorac Surg 1979; 27: 301-304.
25. O'Mara R. Skeletal scanning in neoplastic disease. Cancer 1976; 37: 480-486.